Danish Novo Nordisk is moving out of the diabetes space and taking over Prothenas ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.